https://www.selleckchem.com/products/LBH-589.html
In this fifth phase of development, the contents of the Spanish Asthma Management Guidelines (GEMA), which include versions 5.0 and 5.1, have undergone a thorough review. The aim here is to set the main changes in context. These could be summarized as follows DIAGNOSIS new FENO cut-off and severity classification based on treatment needed to maintain control; INTERMITTENT ASTHMA a more restrictive concept and treatment extended to include a glucocorticoid/adrenergic combination as needed; MILD ASTHMA glucocorticoid/adrenergic therapy as